Clinical Trial Update: Managed Access Programs for LNP023, Iptacopan

View source ↗

Summary

This clinical trial update notes the availability of managed access programs for iptacopan (LNP023) for patients with C3 glomerulopathy and paroxysmal nocturnal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• C3 Glomerulopathy
• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• LNP023 (iptacopan)
• iptacopan (iptacopan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: C3 Glomerulopathy (C3G), Paroxysmal Nocturnal Hemoglobinuria (PNH) | Status: AVAILABLE